JAK inhibitors for the treatment of inflammatory bowel disease: results of an international survey of perceptions, attitudes, and clinical practice.

ABSTRACT:

Background

Janus kinase inhibitors (JAKi) are small molecule drugs with demonstrated efficacy in inflammatory bowel disease (IBD). However, widespread utilisation may be hindered by safety concerns.

Aims

This is the first study assessing risk-benefit perceptions and clinical practices of those using JAKi for IBD.

Methods

A prospective, cross-sectional study was conducted using a 23-item survey distributed to IBD healthcare providers worldwide.

Results

Of 385 respondents from 48 countries, 72% were tertiary-centre based and 50% were gastroenterologists with ≥10 years experience. JAKi were commonly used outside market authorisation (31%), though many (17%) were unconfident discussing JAKi risk-benefit profile and 7% had never prescribed JAKi. If venous thromboemb

SUBMITTER: Honap S 

PROVIDER: S-EPMC10659244 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature